Multidisciplinary treatment for patients with advanced hepatocellular carcinoma complicated by Vp4 portal vein tumor thrombosis: Combination of atezolizumab and bevacizumab after hepatic arterial infusion chemotherapy and radiotherapy: A case series
Abstract
Various treatments are available for treating hepatocellular carcinoma (HCC). Among HCC, Vp4 portal vein tumor thrombosis (PVTT) has a poor prognosis. There have been reports of treatment with molecularly targeted agents in combination with hepatic arterial infusion chemotherapy (HAIC) and radiotherapy (RT) in HCC patients with Vp4 PVTT, but none with atezolizumab, the immune checkpoint inhibitor. Here, we present cases of unresectable HCC with Vp4 PVTT that were treated with the combination atezolizumab and bevacizumab (Atezo + Bev) after HAIC and RT. The purpose and significance of this study are to research the usefulness to precede HAIC and RT in the treatment of HCC with immune checkpoint inhibitors.
Sixty-six-year-old man, 74-year-old man, 83-year-old man, 69-year-old man, 62-year-old man, and 85-year-old woman were diagnosed with HCC with Vp4 PVTT.
Cirrhosis was classified as Child-Pugh class A or B. HCC was diagnosed as TNM stage IVa or IVb.
RT for PVTT was performed the same day or the day after HAIC. Atezo + Bev was started at least 1 week after RT was completed.
Death was confirmed in 4 of the 6 patients; the median overall survival time was not reached. The survival times of the 4 patients were 18.7, 12.5, 5.1, and 1.7 months. Based on the modified response evaluation criteria in solid tumors criteria, the objective response rate of patients with best tumor response to Atezo + Bev therapy was 66.7%, and that of patients with best response of PVVT to Atezo + Bev…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 6 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.